Preface
Preface to the focused issue: up-to-date knowledge of basic and translational research on bladder cancer
Translational Cancer Research
2017;
6
(Suppl 4)
:S655-S656
.
(30 June 2017)
Original Article
Multiplex screening of 422 candidate serum biomarkers in bladder cancer patients identifies syndecan-1 and macrophage colonystimulating factor 1 as prognostic indicators
Translational Cancer Research
2017;
6
(Suppl 4)
:S657-S665
.
(30 June 2017)
Review Article
Emerging targeted therapies in advanced bladder cancer
Translational Cancer Research
2017;
6
(Suppl 4)
:S666-S676
.
(30 June 2017)
Epigenetic regulation in bladder cancer: development of new prognostic targets and therapeutic implications
Translational Cancer Research
2017;
6
(Suppl 4)
:S677-S688
.
(30 June 2017)
The mutational signatures and molecular alterations of bladder cancer
Translational Cancer Research
2017;
6
(Suppl 4)
:S689-S701
.
(30 June 2017)
The role of androgen receptor signaling pathways in bladder cancer
Translational Cancer Research
2017;
6
(Suppl 4)
:S702-S707
.
(30 June 2017)
Autophagy regulation in bladder cancer as the novel therapeutic strategy
Translational Cancer Research
2017;
6
(Suppl 4)
:S708-S719
.
(30 June 2017)
Immune checkpoint inhibitors for metastatic bladder cancer
Translational Cancer Research
2017;
6
(Suppl 4)
:S720-S732
.
(30 June 2017)
Establishment and application of bladder cancer patient-derived xenografts as a novel preclinical platform
Translational Cancer Research
2017;
6
(Suppl 4)
:S733-S743
.
(30 June 2017)
The role of the tumor microenvironment in bladder cancer development and progression
Translational Cancer Research
2017;
6
(Suppl 4)
:S744-S758
.
(30 June 2017)
Disclosure:
The supplement “Bladder Cancer” was commissioned by the editorial office, Translational Cancer Research without any sponsorship or funding. Ja Hyeon Ku, Kunyoo Shin and Minyong Kang served as the unpaid Guest Editors for the supplement.
